Skip to main content
. 2019 Dec 20;122(5):658–667. doi: 10.1038/s41416-019-0688-y

Fig. 3. TAS-116 had anti-tumour effects in xenograft mouse models.

Fig. 3

a GIST cell line xenograft mouse model; BALB/cAJcl-nu/nu mice (6 weeks of age) were injected with 1.0 × 107 cells of GIST T1 and GIST R8, whereas C.B-17/lcr-scid/scidJcl mice (7 weeks of age) were injected with 1.0 × 107 cells of GIST R9. When the tumour volume reached ~150 mm3, xenograft tumours were treated with TAS-116 five times a week orally at 14 mg/kg and IM twice a day orally at 50 mg/kg for 3 weeks. b Tumour volumes were determined twice per week. Statistical analysis was performed using the Tukey-Kramer (HSD) test (*p < 0.01). c Western blot analysis of HSP90, HSP70, pKIT/KIT, pAKT/AKT and pERK/ERK in GIST cell-derived tissues from control, IM-treated and TAS-116–treated animals.